12 Month Price Forecast For ENLV
Distance to ENLV Price Forecasts
ENLV Price Momentum
๐ค Considering Enlivex (ENLV)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 11, 2025 9:45 PM UTC
ENLV Analyst Ratings & Price Targets
Based on our analysis of 3 Wall Street analysts, ENLV has a bullish consensus with a median price target of $9.50 (ranging from $6.00 to $13.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $1.09, the median forecast implies a 771.6% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jason Kolbert at D. Boral Capital, projecting a 1,092.7% upside. Conversely, the most conservative target is provided by Raghuram Selvaraju at HC Wainwright & Co., suggesting a 450.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ENLV Analyst Consensus
ENLV Price Target Range
Latest ENLV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ENLV.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Feb 7, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $13.00 |
Dec 11, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $13.00 |
Dec 3, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $13.00 |
Nov 14, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $13.00 |
Sep 27, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $6.00 |
Sep 26, 2024 | EF Hutton | Jason Kolbert | Buy | Maintains | $13.00 |
Sep 24, 2024 | EF Hutton | Jason Kolbert | Buy | Maintains | $13.00 |
Sep 9, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $6.00 |
Aug 27, 2024 | EF Hutton | Jason Kolbert | Buy | Initiates | $13.00 |
Jun 11, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $6.00 |
Apr 23, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $7.00 |
Apr 12, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $7.00 |
Sep 25, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $12.00 |
Aug 1, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $15.00 |
Apr 24, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $15.00 |
Apr 5, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $15.00 |
Feb 24, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $15.00 |
May 2, 2022 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $15.00 |
Jan 9, 2020 | H.C. Wainwright | Buy | Initiates | $0.00 | |
Jan 9, 2020 | HC Wainwright & Co. | Buy | Initiates | $0.00 |
Stocks Similar to Enlivex Therapeutics Ltd
The following stocks are similar to Enlivex based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Enlivex Therapeutics Ltd (ENLV) Financial Data
Enlivex Therapeutics Ltd has a market capitalization of $24.19M with a P/E ratio of -0.7x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -61.2%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Enlivex Therapeutics Ltd (ENLV) Company Overview
About Enlivex Therapeutics Ltd
Develops immunotherapy for organ dysfunction and osteoarthritis.
The company operates as a clinical-stage entity focused on macrophage reprogramming immunotherapy, primarily generating revenue through the development and eventual commercialization of its lead product, Allocetra. It is currently in various phases of clinical trials targeting conditions like sepsis and knee osteoarthritis, aiming to secure partnerships or licensing agreements to monetize its innovations.
Enlivex Therapeutics is based in Ness Ziona, Israel, and is actively pursuing treatments that address significant unmet medical needs, which may enhance its market potential and attract investment as clinical trials progress.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
0
CEO
Country
Israel
IPO Year
N/A
Website
www.enlivex.comEnlivex Therapeutics Ltd (ENLV) Latest News & Analysis
RedChip Companies will feature interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on Bloomberg TV's RedChip show on January 11 at 7 p.m.
The interviews could boost visibility and interest in Enlivex and bioAffinity, potentially impacting their stock performance and attracting new investors.
Enlivex Therapeutics has received Israeli Ministry of Health approval to start a Phase I trial for Allocetraโข in TMJ osteoarthritis patients, focusing on safety and efficacy.
The initiation of a Phase I trial for Allocetraโข could signal potential advancements in treatment options, affecting Enlivex's stock performance and market perception in immunotherapy.
Enlivex Therapeutics (Nasdaq: ENLV) reported positive interim efficacy data from its Phase I/II Allocetraโข trial for knee osteoarthritis.
Positive interim results from Enlivex's trial could boost investor confidence, indicating potential for future market success and increased stock value in the biopharmaceutical sector.
Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3
2 months agoEnlivex Therapeutics Ltd. (Nasdaq:ENLV) will host a webinar for investors on December 3, 2024, at 11:00 a.m. regarding their macrophage reprogramming immunotherapy developments.
The webinar announcement signals potential updates on Enlivex's clinical progress, which could influence stock performance and investor sentiment.
Enlivex Therapeutics has completed dosing for the first patient in its Phase I trial of Allocetraโข for psoriatic arthritis, reporting no safety concerns.
Completion of initial dosing in Enlivex's Phase I trial for Allocetraโข indicates progress in drug development for psoriatic arthritis, potentially enhancing the company's valuation and investor confidence.
Enlivex Therapeutics announced the Japanese Patent Office will issue a patent for therapeutic apoptotic cells for osteoarthritis, providing IP protection until at least 2040.
Enlivex's new patent for osteoarthritis treatment enhances its IP protection, potentially increasing its market value and competitive advantage, which may attract investor interest.
Frequently Asked Questions About ENLV Stock
What is Enlivex Therapeutics Ltd's (ENLV) stock forecast for 2025?
Based on our analysis of 3 Wall Street analysts, Enlivex Therapeutics Ltd (ENLV) has a median price target of $9.50. The highest price target is $13.00 and the lowest is $6.00.
Is ENLV stock a good investment in 2025?
According to current analyst ratings, ENLV has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.09. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for ENLV stock?
Wall Street analysts predict ENLV stock could reach $9.50 in the next 12 months. This represents a 771.6% increase from the current price of $1.09. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Enlivex Therapeutics Ltd's business model?
The company operates as a clinical-stage entity focused on macrophage reprogramming immunotherapy, primarily generating revenue through the development and eventual commercialization of its lead product, Allocetra. It is currently in various phases of clinical trials targeting conditions like sepsis and knee osteoarthritis, aiming to secure partnerships or licensing agreements to monetize its innovations.
What is the highest forecasted price for ENLV Enlivex Therapeutics Ltd?
The highest price target for ENLV is $13.00 from Jason Kolbert at D. Boral Capital, which represents a 1,092.7% increase from the current price of $1.09.
What is the lowest forecasted price for ENLV Enlivex Therapeutics Ltd?
The lowest price target for ENLV is $6.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 450.5% increase from the current price of $1.09.
What is the overall ENLV consensus from analysts for Enlivex Therapeutics Ltd?
The overall analyst consensus for ENLV is bullish. Out of 3 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $9.50.
How accurate are ENLV stock price projections?
Stock price projections, including those for Enlivex Therapeutics Ltd, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.